Screener
Crinetics Pharmaceuticals CRNX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $114,341 | $101,536 |
| Investment securities, amortized cost of $1,178,076 at March 31, 2026 and $924,317 at December 31, 2025 | 1,176,965 | 926,353 |
| Trade accounts receivable, net | 5,683 | 592 |
| Inventory | 3,064 | 2,022 |
| Prepaid expenses and other current assets | 22,361 | 17,839 |
| Total current assets | 1,322,414 | 1,048,342 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's short-term investments?
- Crinetics Pharmaceuticals (CRNX) reported short-term investments of $1.18B in Q1 2026.
- How has Crinetics Pharmaceuticals's short-term investments changed year-over-year?
- Crinetics Pharmaceuticals's short-term investments decreased by 0.2% year-over-year, from $1.18B to $1.18B.
- What is the long-term trend for Crinetics Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's short-term investments has grown at a 64.1% compound annual growth rate (CAGR), from $77.79M to $926.35M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Crinetics Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude